GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Cash Receipts from Securities Related Activities

Arovella Therapeutics (FRA:E4NA) Cash Receipts from Securities Related Activities


View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics Cash Receipts from Securities Related Activities?

Cash Receipts from Securities Related Activities only applies to banks.


Arovella Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Cash Receipts from Securities Related Activities
Traded in Other Exchanges
Address
84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.